AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Arvinas Presents Preclinical Data for ARV-393 BCL6 Degrader at EHA 2025 Congress
ByAinvest
Friday, Jun 13, 2025 7:16 am ET1min read
Arvinas presented preclinical data for ARV-393, a PROTAC BCL6 degrader, at the European Hematology Association 2025 Congress. ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type, and transformed follicular lymphoma. In combination with small molecule inhibitors, ARV-393 showed enhanced tumor growth inhibition and tumor regressions in models of aggressive diffuse large B-cell lymphoma.
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company, presented preclinical data for ARV-393, an investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader, at the European Hematology Association 2025 Congress in Milan, Italy. The data demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL), and transformed follicular lymphoma. Additionally, ARV-393 showed enhanced tumor growth inhibition and tumor regressions in combination with small molecule inhibitors in models of aggressive diffuse large B-cell lymphoma (DLBCL).The preclinical studies, presented in a poster titled "ARV-393, a PROTAC BCL6 Degrader, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular Lymphoma," highlighted the potential of ARV-393 in addressing unmet needs in B-cell lymphoma. The data indicated that ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow, and spleen in a systemic patient-derived xenograft (PDX) model of AITL derived from a patient who relapsed post chemotherapy. The study also found that ARV-393 monotherapy resulted in robust (≥95%) tumor growth inhibition (TGI) in two PDX models of transformed follicular lymphoma (tFL). In combination with oral small molecule inhibitors (SMIs), ARV-393 demonstrated increased TGI in cell line-derived xenograft (CDX) models of high-grade B-cell lymphoma (HGBCL) and aggressive DLBCL compared to the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax.
The results from these preclinical studies suggest the broad utility of ARV-393 across non-Hodgkin lymphoma subtypes with unmet need beyond DLBCL and provide a compelling rationale for considering combination strategies, including chemotherapy-free approaches. A Phase 1 study of ARV-393 is currently enrolling adult patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL and AITL (NCT06393738).
[1] https://www.globenewswire.com/news-release/2025/06/13/3098932/0/en/Arvinas-Presents-Preclinical-Data-for-PROTAC-BCL6-Degrader-ARV-393-at-the-European-Hematology-Association-2025-Congress.html
[2] https://finance.yahoo.com/quote/ARVN/press-releases/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet